National Health Act (Pharmaceutical Benefits - Early Supply) Instrument 2009 - specification under subsection 84AAA(2) (No. PB 30 of 2009) (Cth)
Case
No judgment structure available for this case.
National Health Act (Pharmaceutical Benefits—Early Supply) Instrument 2009—specification under subsection 84AAA(2) (PB 30 of 2009)
made under subsection 84AAA(2) of the
National Health Act 1953
Compilation No. 50
Compilation date: 1 December 2015
Includes amendments up to: PB 110 of 2015
Registered: 2 December 2015
About this compilation
This compilation
This is a compilation of the National Health Act (Pharmaceutical Benefits—Early Supply) Instrument 2009—specification under subsection 84AAA(2) (PB 30 of 2009) that shows the text of the law as amended and in force on 1 December 2015 (the compilation date).
This compilation was prepared on 2 December 2015.
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on ComLaw ( The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on ComLaw for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on ComLaw for the compiled law.
Self-repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Contents
1............ Name of Instrument....................................................................................................... 1
2............ Commencement............................................................................................................. 1
3............ Revocation..................................................................................................................... 1
4............ Definitions..................................................................................................................... 1
5............ Specification of pharmaceutical items............................................................................ 1
6............ Circumstances relating to specification of pharmaceutical items.................................... 1
Schedule 1—Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply 3
Endnotes31
Endnote 1—About the endnotes 31
Endnote 2—Abbreviation key 32
Endnote 3—Legislation history 33
Endnote 4—Amendment history 36
1 Name of Instrument
(1) This Instrument is the National Health Act (Pharmaceutical Benefits—Early Supply) Instrument 2009—specification under subsection 84AAA(2).
(2) This Instrument may also be cited as “No. PB 30 of 2009”.
2 Commencement
This Instrument commences on 1 May 2009.
3 Revocation
The National Health (Pharmaceutical Benefits – early supply) Instrument 2005 is revoked.
4 Definitions
In this Instrument:
Act means the National Health Act 1953.
I.U. means international unit.
Mg means milligram.
Ml means millilitre.
5 Specification of pharmaceutical items
(1) For paragraph 84AAA(1)(b) of the Act, a pharmaceutical item in a pharmaceutical benefit is specified if:
(a) the item is mentioned in Schedule 1; and
(b) all the circumstances identified in section 6 as applying to the benefit exist in relation to a benefit that has the item in Schedule 1.
(2) A pharmaceutical item in Schedule 1 is identified by the name of the listed drug, the form of the listed drug, and the manner of administration of that form of the listed drug.
6 Circumstances relating to specification of pharmaceutical items
For paragraph 5(1)(b), the circumstances are as follows:
(1) the form of a pharmaceutical benefit that has the pharmaceutical item mentioned in the table in Schedule 1 is the same as the form of the pharmaceutical item determined under subsection 85(3) of the Act;
(2) the manner of administration of a benefit that has the item mentioned in the table is the same as the manner of administration of the item determined under subsection 85(5) of the Act;
(3) the maximum quantity or number of units mentioned in the table for a benefit that has the item is the same as the maximum quantity or number of units determined under paragraph 85A(2)(a) of the Act;
(4) the maximum number of repeats mentioned in the table for a benefit that has the item is the same as the maximum number of repeats determined under paragraph 85A(2)(b) of the Act;
(5) any other circumstance for paragraph 84AAA(3)(b) of the Act that is mentioned for a benefit that has the item in the table.
Schedule 1—Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply
| Pharmaceutical item | Circumstances | ||||
| Listed drug | Form | Manner of administration | Maximum quantity or number of units | Maximum number of repeats | Other circumstances (if any) for a pharmaceutical benefit that has the item |
| Abatacept | Injection 125 mg in 1 mL single dose pre‑filled syringe | Injection | 4 | 5 | |
| Aciclovir | Tablet 200 mg | Oral | 90 | 5 | |
| Aclidinium | Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses | Inhalation by mouth | 1 | 5 | |
| Aclidinium with eformoterol | Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | 1 | 5 | 1 |
| Adalimumab | Injection 20 mg in 0.4 mL pre-filled pen | Injection | 2 | 5 | |
| Injection 40 mg in 0.8 mL pre‑filled pen | Injection | 2 | 5 | ||
| Injection 40 mg in 0.8 mL pre‑filled syringe | Injection | 2 | 5 | ||
| Alendronic Acid | Tablet 70 mg (as alendronate sodium) | Oral | 4 | 5 | |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral | 4 | 5 | |
| Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral | 4 | 5 | ||
| Alendronic acid with colecalciferol and calcium | Pack containing 4 tablets containing alendronic acid 70 mg (as alendronate sodium) with 140 micrograms colecalciferol and 48 tablets calcium 500 mg (as carbonate) | Oral | 1 | 5 | |
| Amantadine | Capsule containing amantadine hydrochloride 100 mg | Oral | 100 | 5 | |
| Amlodipine | Tablet 5 mg (as besylate) | Oral | 30 | 5 | |
| Tablet 10 mg (as besylate) | Oral | 30 | 5 | ||
| Amlodipine with atorvastatin | Tablet 5 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium) | Oral | 30 | 5 | |
| Tablet 5 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium) | Oral | 30 | 5 | ||
| Tablet 5 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium) | Oral | 30 | 5 | ||
| Tablet 5 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium) | Oral | 30 | 5 | ||
| Tablet 10 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium) | Oral | 30 | 5 | ||
| Tablet 10 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium) | Oral | 30 | 5 | ||
| Tablet 10 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium) | Oral | 30 | 5 | ||
| Tablet 10 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium) | Oral | 30 | 5 | ||
| Amlodipine with valsartan | Tablet 5 mg (as besylate)‑80 mg | Oral | 28 | 5 | |
| Tablet 5 mg (as besylate)‑160 mg | Oral | 28 | 5 | ||
| Tablet 5 mg (as besylate)‑320 mg | Oral | 28 | 5 | ||
| Tablet 10 mg (as besylate)‑160 mg | Oral | 28 | 5 | ||
| Tablet 10 mg (as besylate)‑320 mg | Oral | 28 | 5 | ||
| Amlodipine with valsartan and hydrochlorothiazide | Tablet 5 mg (as besylate)‑160 mg‑12.5 mg | Oral | 28 | 5 | |
| Tablet 5 mg (as besylate)‑160 mg‑25 mg | Oral | 28 | 5 | ||
| Tablet 10 mg (as besylate)‑160 mg‑12.5 mg | Oral | 28 | 5 | ||
| Tablet 10 mg (as besylate)‑160 mg‑25 mg | Oral | 28 | 5 | ||
| Tablet 10 mg (as besylate)‑320 mg‑25 mg | Oral | 28 | 5 | ||
| Anastrozole | Tablet 1 mg | Oral | 30 | 5 | |
| Apixaban | Tablet 2.5mg | Oral | 60 | 5 | |
| Tablet 5mg | Oral | 60 | 5 | ||
| Aripiprazole | Powder for injection 300 mg (as monohydrate) with diluent | Injection | 1 | 5 | |
| Powder for injection 400 mg (as monohydrate) with diluent | Injection | 1 | 5 | ||
| Atenolol | Tablet 50 mg | Oral | 30 | 5 | |
| Oral solution 50 mg in 10 mL, 300 mL | Oral | 1 | 5 | ||
| Atomoxetine | Capsule 10 mg (as hydrochloride) | Oral | 56 | 5 | |
| Capsule 18 mg (as hydrochloride) | Oral | 56 | 5 | ||
| Capsule 25 mg (as hydrochloride) | Oral | 56 | 5 | ||
| Capsule 40 mg (as hydrochloride) | Oral | 56 | 5 | ||
| Capsule 60 mg (as hydrochloride) | Oral | 56 | 5 | ||
| Capsule 80 mg (as hydrochloride) | Oral | 28 | 5 | ||
| Capsule 100 mg (as hydrochloride) | Oral | 28 | 5 | ||
| Atorvastatin | Tablet 10 mg (as calcium) | Oral | 30 | 5 | |
| Tablet 10 mg (as calcium) | Oral | 30 | 11 | ||
| Tablet 20 mg (as calcium) | Oral | 30 | 5 | ||
| Tablet 20 mg (as calcium) | Oral | 30 | 11 | ||
| Tablet 40 mg (as calcium) | Oral | 30 | 5 | ||
| Tablet 40 mg (as calcium) | Oral | 30 | 11 | ||
| Tablet 80 mg (as calcium) | Oral | 30 | 5 | ||
| Tablet 80 mg (as calcium) | Oral | 30 | 11 | ||
| Atorvastatin with ezetimibe | Pack containing 30 tablets atorvastatin 10 mg (as calcium) and 30 tablets ezetimibe 10 mg | Oral | 1 | 5 | |
| Pack containing 30 tablets atorvastatin 20 mg (as calcium) and 30 tablets ezetimibe 10 mg | Oral | 1 | 5 | ||
| Pack containing 30 tablets atorvastatin 40 mg (as calcium) and 30 tablets ezetimibe 10 mg | Oral | 1 | 5 | ||
| Pack containing 30 tablets atorvastatin 80 mg (as calcium) and 30 tablets ezetimibe 10 mg | Oral | 1 | 5 | ||
| Auranofin | Capsule 3 mg | Oral | 60 | 5 | |
| Tablet 3 mg | Oral | 60 | 5 | ||
| Baclofen | Tablet 10 mg | Oral | 100 | 5 | |
| Tablet 25 mg | Oral | 100 | 5 | ||
| Balsalazide | Capsule containing balsalazide sodium 750 mg | Oral | 180 | 5 | |
| Betaine | Oral powder 180 g | Oral | 1 | 5 | |
| Bicalutamide | Tablet 50 mg | Oral | 28 | 5 | |
| Bisoprolol | Tablet containing bisoprolol fumarate 2.5 mg | Oral | 28 | 5 | |
| Tablet containing bisoprolol fumarate 5 mg | Oral | 28 | 5 | ||
| Tablet containing bisoprolol fumarate 10 mg | Oral | 28 | 5 | ||
| Cabergoline | Tablet 1 mg | Oral | 30 | 5 | |
| Tablet 2 mg | Oral | 30 | 5 | ||
| Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | 30 | 5 | |
| Tablet containing candesartan cilexetil 8 mg | Oral | 30 | 5 | ||
| Tablet containing candesartan cilexetil 16 mg | Oral | 30 | 5 | ||
| Tablet containing candesartan cilexetil 32 mg | Oral | 30 | 5 | ||
| Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg | Oral | 30 | 5 | |
| Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | Oral | 30 | 5 | ||
| Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | Oral | 30 | 5 | ||
| Captopril | Tablet 12.5 mg | Oral | 90 | 5 | |
| Tablet 25 mg | Oral | 90 | 5 | ||
| Tablet 50 mg | Oral | 90 | 5 | ||
| Carvedilol | Tablet 6.25 mg | Oral | 60 | 5 | |
| Tablet 12.5 mg | Oral | 60 | 5 | ||
| Tablet 25 mg | Oral | 60 | 5 | ||
| Certolizumab pegol | Injection 200 mg in 1 mL single use pre‑filled syringe | Injection | 2 | 5 | |
| Cimetidine | Tablet 400 mg | Oral | 60 | 5 | |
| Clonidine | Tablet containing clonidine hydrochloride 100 micrograms | Oral | 100 | 5 | |
| Tablet containing clonidine hydrochloride 150 micrograms | Oral | 100 | 5 | ||
| Clopidogrel | Tablet 75 mg | Oral | 28 | 5 | |
| Tablet 75 mg (as hydrogen sulfate) | Oral | 28 | 5 | ||
| Tablet 75 mg (as besilate) | Oral | 28 | 5 | ||
| Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)‑100 mg | Oral | 30 | 5 | |
| Dabigatran etexilate | Capsule 110 mg (as mesilate) | Oral | 60 | 5 | |
| Capsule 150 mg (as mesilate) | Oral | 60 | 5 | ||
| Dalteparin | Injection containing dalteparin sodium 7,500 I.U. (anti‑Xa) in 0.75 mL single dose pre‑filled syringe | Injection | 30 | 5 | |
| Injection containing dalteparin sodium 10,000 I.U. (anti‑Xa) in 1 mL single dose pre‑filled syringe | Injection | 30 | 5 | ||
| Injection containing dalteparin sodium 12,500 I.U. (anti‑Xa) in 0.5 mL single dose pre‑filled syringe | Injection | 30 | 5 | ||
| Injection containing dalteparin sodium 15,000 I.U. (anti‑Xa) in 0.6 mL single dose pre‑filled syringe | Injection | 30 | 5 | ||
| Injection containing dalteparin sodium 18,000 I.U. (anti‑Xa) in 0.72 mL single dose pre‑filled syringe | Injection | 30 | 5 | ||
| Degarelix | Powder for injection 80 mg (as acetate), injection set | Injection | 1 | 5 | |
| Denosumab | Injection 120 mg in 1.7 mL | Injection | 1 | 5 | Bone metastases The condition must be due to castration‑resistant prostate cancer Bone metastases The condition must be due to breast cancer |
| Diltiazem | Tablet containing diltiazem hydrochloride 60 mg | Oral | 90 | 5 | |
| Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | Oral | 30 | 5 | ||
| Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | Oral | 30 | 5 | ||
| Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | Oral | 30 | 5 | ||
| Dipyridamole | Capsule 200 mg (sustained release) | Oral | 60 | 5 | |
| Dipyridamole with aspirin | Capsule 200 mg (sustained release)25 mg | Oral | 60 | 5 | |
| Dutasteride | Capsule 500 micrograms | Oral | 30 | 5 | |
| Dutasteride with Tamsulosin | Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms | Oral | 30 | 5 | |
| Empagliflozin | Tablet 10 mg | Oral | 30 | 5 | |
| Tablet 25 mg | Oral | 30 | 5 | ||
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | 30 | 5 | |
| Tablet containing enalapril maleate 10 mg | Oral | 30 | 5 | ||
| Tablet containing enalapril maleate 20 mg | Oral | 30 | 5 | ||
| Enalapril with Hydrochlorothiazide | Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg | Oral | 30 | 5 | |
| Enzalutamide | Capsule 40 mg | Oral | 112 | 2 | |
| Eplerenone | Tablet 25 mg | Oral | 30 | 5 | |
| Tablet 50 mg | Oral | 30 | 5 | ||
| Eprosartan | Tablet 400 mg (as mesylate) | Oral | 56 | 5 | |
| Tablet 600 mg (as mesylate) | Oral | 28 | 5 | ||
| Eprosartan with hydrochlorothiazide | Tablet 600 mg eprosartan (as mesylate) with 12.5 mg hydrochlorothiazide | Oral | 28 | 5 | |
| Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | Oral | 30 | 5 | |
| Capsule (enteric) 40 mg (as magnesium) | Oral | 30 | 5 | ||
| Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | 30 | 5 | ||
| Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | 30 | 5 | ||
| Etanercept | Injection set containing 4 vials powder for injection 25 mg and 4 pre‑filled syringes solvent 1 mL | Injection | 2 | 5 | |
| Injections 50 mg in 1 mL single use pre‑filled syringes, 4 | Injection | 1 | 5 | ||
| Injection 50 mg in 1 mL single use auto‑injector, 4 | Injection | 1 | 5 | ||
| Ezetimibe | Tablet 10 mg | Oral | 30 | 5 | |
| Ezetemibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) | Oral | 1 | 5 | |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) | Oral | 1 | 5 | ||
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) | Oral | 1 | 5 | ||
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) | Oral | 1 | 5 | ||
| Ezetimibe with atorvastatin | Tablet 10 mg-10 mg | Oral | 30 | 5 | |
| Tablet 10 mg-20 mg | Oral | 30 | 5 | ||
| Tablet 10 mg-40 mg | Oral | 30 | 5 | ||
| Tablet 10 mg-80 mg | Oral | 30 | 5 | ||
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | 30 | 5 | |
| Tablet 10 mg‑20 mg | Oral | 30 | 5 | ||
| Tablet 10 mg‑40 mg | Oral | 30 | 5 | ||
| Tablet 10 mg‑80 mg | Oral | 30 | 5 | ||
| Famciclovir | Tablet 250 mg | Oral | 56 | 5 | |
| Tablet 500 mg | Oral | 56 | 5 | ||
| Famotidine | Tablet 20 mg | Oral | 60 | 5 | |
| Tablet 40 mg | Oral | 30 | 5 | ||
| Febuxostat | Tablet 80 mg | Oral | 28 | 5 | |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | 30 | 5 | |
| Tablet 5 mg (extended release) | Oral | 30 | 5 | ||
| Tablet 10 mg (extended release) | Oral | 30 | 5 | ||
| Fenofibrate | Tablet 48 mg | Oral | 60 | 5 | |
| Tablet 48 mg | Oral | 60 | 11 | ||
| Tablet 145 mg | Oral | 30 | 5 | ||
| Tablet 145 mg | Oral | 30 | 11 | ||
| Fludarabine | Tablet containing fludarabine phosphate 10 mg | Oral | 20 | 5 | |
| Flutamide | Tablet 250 mg | Oral | 100 | 5 | |
| Fluvastatin | Tablet (prolonged release) 80 mg (as sodium) | Oral | 28 | 5 | |
| Tablet (prolonged release) 80 mg (as sodium) | Oral | 28 | 11 | ||
| Fosinopril | Tablet containing fosinopril sodium 10 mg | Oral | 30 | 5 | |
| Tablet containing fosinopril sodium 20 mg | Oral | 30 | 5 | ||
| Fosinopril with hydrochlorothiazide | Tablet containing fosinopril sodium 10 mg with hydrochlorothiazide 12.5 mg | Oral | 30 | 5 | |
| Tablet containing fosinopril sodium 20 mg with hydrochlorothiazide 12.5 mg | Oral | 30 | 5 | ||
| Gemfibrozil | Tablet 600 mg | Oral | 60 | 5 | |
| Tablet 600 mg | Oral | 60 | 11 | ||
| Glyceryl trinitrate | Transdermal patch 18 mg | Transdermal | 30 | 5 | |
| Transdermal patch 25 mg | Transdermal | 30 | 5 | ||
| Transdermal patch 36 mg | Transdermal | 30 | 5 | ||
| Transdermal patch 40 mg | Transdermal | 30 | 5 | ||
| Transdermal patch 50 mg | Transdermal | 30 | 5 | ||
| Transdermal patch 54 mg | Transdermal | 30 | 5 | ||
| Transdermal patch 80 mg | Transdermal | 30 | 5 | ||
| Transdermal patch 120 mg | Transdermal | 30 | 5 | ||
| Glycopyrronium | Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler) | Inhalation by mouth | 30 | 5 | |
| Golimumab | Injection 50 mg in 0.5 mL single use pre‑filled pen | Injection | 1 | 5 | |
| Injection 50 mg in 0.5 mL single use pre‑filled syringe | Injection | 1 | 5 | ||
| Goserelin and bicalutamide | Pack containing 1 subcutaneous implant containing goserelin 3.6 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg | Implantation/ oral | 1 | 5 | |
| Imatinib | Tablet 100 mg (as mesylate) | Oral | 60 | 5 | |
| Tablet 400 mg (as mesylate) | Oral | 30 | 5 | ||
| Indacaterol | Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler) | Inhalation by mouth | 30 | 5 | |
| Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler) | Inhalation by mouth | 30 | 5 | ||
| Indacaterol with glycopyrronium | Capsule containing powder for oral inhalation indacaterol 110 micrograms (as maleate) with glycopyrronium 50 micrograms (as bromide) (for use in Breezhaler) | Inhalation by mouth | 30 | 5 | |
| Irbesartan | Tablet 75 mg | Oral | 30 | 5 | |
| Tablet 150 mg | Oral | 30 | 5 | ||
| Tablet 300 mg | Oral | 30 | 5 | ||
| Irbesartan with hydrochlorothiazide | Tablet 150 mg‑12.5 mg | Oral | 30 | 5 | |
| Tablet 300 mg‑12.5 mg | Oral | 30 | 5 | ||
| Tablet 300 mg‑25 mg | Oral | 30 | 5 | ||
| Isosorbide mononitrate | Tablet 60 mg (sustained release) | Oral | 30 | 5 | |
| Tablet 120 mg (sustained release) | Oral | 30 | 5 | ||
| Ivabradine | Tablet 5 mg | Oral | 56 | 5 | |
| Tablet 7.5 mg | Oral | 56 | 5 | ||
| Labetalol | Tablet containing labetalol hydrochloride 100 mg | Oral | 100 | 5 | |
| Tablet containing labetalol hydrochloride 200 mg | Oral | 100 | 5 | ||
| Lansoprazole | Capsule 15 mg | Oral | 30 | 5 | |
| Capsule 30 mg | Oral | 28 | 5 | ||
| Tablet 15 mg (orally disintegrating) | Oral | 28 | 5 | ||
| Tablet 30 mg (orally disintegrating) | Oral | 28 | 5 | ||
| Leflunomide | Tablet 10 mg | Oral | 30 | 5 | |
| Tablet 20 mg | Oral | 30 | 5 | ||
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | 28 | 5 | |
| Tablet containing lercanidipine hydrochloride 20 mg | Oral | 28 | 5 | ||
| Lercanidipine with enalapril | Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg | Oral | 28 | 5 | |
| Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg | Oral | 28 | 5 | ||
| Letrozole | Tablet 2.5 mg | Oral | 30 | 5 | |
| Leuprorelin | I.M. injection (modified release), powder for injection containing leuprorelin acetate 7.5 mg with diluent in pre‑filled dual‑chamber syringe | Injection | 1 | 5 | |
| Lisinopril | Tablet 5 mg | Oral | 30 | 5 | |
| Tablet 10 mg | Oral | 30 | 5 | ||
| Tablet 20 mg | Oral | 30 | 5 | ||
| Losartan | Tablet containing losartan potassium 25 mg | Oral | 30 | 5 | |
| Tablet containing losartan potassium 50 mg | Oral | 60 | 5 | ||
| Mesalazine | Sachet containing granules, 500 mg per sachet | Oral | 200 | 5 | |
| Sachet containing granules, 1 g per sachet | Oral | 100 | 5 | ||
| Sachet containing granules, 1.5 g per sachet | Oral | 60 | 5 | ||
| Sachet containing granules, 3 g per sachet | Oral | 30 | 5 | ||
| Sachet containing prolonged release granules, 1 g per sachet | Oral | 120 | 5 | ||
| Sachet containing prolonged release granules, 2 g per sachet | Oral | 60 | 5 | ||
| Sachet containing prolonged release granules, 4 g per sachet | Oral | 30 | 5 | ||
| Tablet 250 mg (enteric coated) | Oral | 100 | 5 | ||
| Tablet 500 mg (enteric coated) | Oral | 200 | 5 | ||
| Tablet 500 mg (prolonged release) | Oral | 200 | 5 | ||
| Tablet 1 g (prolonged release) | Oral | 120 | 5 | ||
| Tablet 1.2 g (prolonged release) | Oral | 60 | 5 | ||
| Methyldopa | Tablet 250 mg | Oral | 100 | 5 | |
| Metoprolol | Tablet containing metoprolol tartrate 50 mg | Oral | 100 | 5 | |
| Tablet containing metoprolol tartrate 100 mg | Oral | 60 | 5 | ||
| Metoprolol succinate | Tablet 47.5 mg (controlled release) | Oral | 30 | 5 | |
| Tablet 95 mg (controlled release) | Oral | 30 | 5 | ||
| Tablet 190 mg (controlled release) | Oral | 30 | 5 | ||
| Minocycline | Tablet 50 mg (as hydrochloride) | Oral | 60 | 5 | |
| Minoxidil | Tablet 10 mg | Oral | 100 | 5 | |
| Modafinil | Tablet 100 mg | Oral | 120 | 5 | |
| Moxonidine | Tablet 200 micrograms | Oral | 30 | 5 | |
| Tablet 400 micrograms | Oral | 30 | 5 | ||
| Nebivolol | Tablet 1.25 mg (as hydrochloride) | Oral | 56 | 5 | |
| Tablet 5 mg (as hydrochloride) | Oral | 28 | 5 | ||
| Tablet 10 mg (as hydrochloride) | Oral | 28 | 5 | ||
| Nicorandil | Tablets 10 mg, 60 | Oral | 1 | 5 | |
| Tablets 20 mg, 60 | Oral | 1 | 5 | ||
| Nifedipine | Tablet 10 mg | Oral | 60 | 5 | |
| Tablet 20 mg | Oral | 60 | 5 | ||
| Tablet 20 mg (controlled release) | Oral | 30 | 5 | ||
| Tablet 30 mg (controlled release) | Oral | 30 | 5 | ||
| Tablet 60 mg (controlled release) | Oral | 30 | 5 | ||
| Nilotinib | Capsule 150 mg (as hydrochloride monohydrate) | Oral | 120 | 5 | |
| Capsule 200 mg (as hydrochloride monohydrate) | Oral | 120 | 5 | ||
| Nilutamide | Tablet 150 mg | Oral | 30 | 5 | |
| Nizatidine | Capsule 150 mg | Oral | 60 | 5 | |
| Capsule 300 mg | Oral | 30 | 5 | ||
| Oestradiol | Transdermal patches 390 micrograms, 8 | Transdermal | 1 | 5 | |
| Transdermal patches 585 micrograms, 8 | Transdermal | 1 | 5 | ||
| Transdermal patches 750 micrograms (as hemihydrate), 8 | Transdermal | 1 | 5 | ||
| Transdermal patches 780 micrograms, 8 | Transdermal | 1 | 5 | ||
| Transdermal patches 1.17 mg, 8 | Transdermal | 1 | 5 | ||
| Transdermal patches 1.5 mg (as hemihydrate), 8 | Transdermal | 1 | 5 | ||
| Transdermal patches 1.56 mg, 8 | Transdermal | 1 | 5 | ||
| Transdermal patches 2 mg, 4 | Transdermal | 1 | 5 | ||
| Transdermal patches 3 mg (as hemihydrate), 8 | Transdermal | 1 | 5 | ||
| Transdermal patches 3.8 mg, 4 | Transdermal | 1 | 5 | ||
| Transdermal patches 5.7 mg, 4 | Transdermal | 1 | 5 | ||
| Transdermal patches 7.6 mg, 4 | Transdermal | 1 | 5 | ||
| Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28 | Transdermal | 1 | 5 | ||
| Oestradiol and oestradiol with dydrogesterone | Pack containing 14 tablets oestradiol 1 mg and 14 tablets oestradiol 1 mg with dydrogesterone 10 mg | Oral | 1 | 5 | |
| Pack containing 14 tablets oestradiol 2 mg and 14 tablets oestradiol 2 mg with dydrogesterone 10 mg | Oral | 1 | 5 | ||
| Oestradiol and oestradiol with norethisterone | Pack containing 4 transdermal patches 780 micrograms oestradiol (as hemihydrate) and 4 transdermal patches 510 micrograms oestradiol (as hemihydrate) with 4.8 mg norethisterone acetate | Transdermal | 1 | 5 | |
| Pack containing 4 transdermal patches 780 micrograms oestradiol (as hemihydrate) and 4 transdermal patches 620 micrograms oestradiol (as hemihydrate) with 2.7 mg norethisterone acetate | Transdermal | 1 | 5 | ||
| Oestradiol with dydrogesterone | Tablet 1 mg-5 mg | Oral | 28 | 5 | |
| Oestradiol with norethisterone | Transdermal patches containing 510 micrograms oestradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 | Transdermal | 1 | 5 | |
| Transdermal patches containing 620 micrograms oestradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 | Transdermal | 1 | 5 | ||
| Olmesartan | Tablet containing olmesartan medoxomil 20 mg | Oral | 30 | 5 | |
| Tablet containing olmesartan medoxomil 40 mg | Oral | 30 | 5 | ||
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besylate) | Oral | 30 | 5 | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besylate) | Oral | 30 | 5 | ||
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besylate) | Oral | 30 | 5 | ||
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besylate) and hydrochlorothiazide 12.5 mg | Oral | 30 | 5 | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besylate) and hydrochlorothiazide 12.5 mg | Oral | 30 | 5 | ||
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besylate) and hydrochlorothiazide 25 mg | Oral | 30 | 5 | ||
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besylate ) and hydrochlorothiazide 12.5 mg | Oral | 30 | 5 | ||
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besylate) and hydrochlorothiazide 25 mg | Oral | 30 | 5 | ||
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | 30 | 5 | |
| Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | 30 | 5 | ||
| Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | 30 | 5 | ||
| Olsalazine | Capsule containing olsalazine sodium 250 mg | Oral | 100 | 5 | |
| Tablet containing olsalazine sodium 500 mg | Oral | 100 | 5 | ||
| Omeprazole | Tablet 10 mg (as magnesium) | Oral | 30 | 5 | |
| Tablet 20 mg (as magnesium) | Oral | 30 | 5 | ||
| Tablet 20 mg | Oral | 30 | 5 | ||
| Capsule 20 mg | Oral | 30 | 5 | ||
| Oxprenolol | Tablet containing oxprenolol hydrochloride 40 mg | Oral | 100 | 5 | |
| Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral | 30 | 5 | |
| Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | 30 | 5 | ||
| Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | 30 | 5 | ||
| Pazopanib | Tablet 200 mg (as hydrochloride) | Oral | 30 | 5 | |
| 90 | 5 | ||||
| Tablet 400 mg (as hydrochloride) | Oral | 30 | 5 | ||
| 60 | 5 | ||||
| Perhexiline | Tablet containing perhexiline maleate 100 mg | Oral | 100 | 5 | |
| Perindopril | Tablet containing perindopril arginine 2.5 mg | Oral | 30 | 5 | |
| Tablet containing perindopril arginine 5 mg | Oral | 30 | 5 | ||
| Tablet containing perindopril arginine 10 mg | Oral | 30 | 5 | ||
| Tablet containing perindopril erbumine 2 mg | Oral | 30 | 5 | ||
| Tablet containing perindopril erbumine 4 mg | Oral | 30 | 5 | ||
| Tablet containing perindopril erbumine 8 mg | Oral | 30 | 5 | ||
| Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besylate) | Oral | 30 | 5 | |
| Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besylate) | Oral | 30 | 5 | ||
| Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besylate) | Oral | 30 | 5 | ||
| Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besylate) | Oral | 30 | 5 | ||
| Perindopril with indapamide | Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg | Oral | 30 | 5 | |
| Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | 30 | 5 | ||
| Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg | Oral | 30 | 5 | ||
| Phenoxybenzamine | Capsule containing phenoxybenzamine hydrochloride 10 mg | Oral | 100 | 5 | |
| Capsule containing 10 mg phenoxybenzamine hydrochloride | Oral | 100 | 5 | ||
| Pindolol | Tablet 5 mg | Oral | 100 | 5 | |
| Tablet 15 mg | Oral | 50 | 5 | ||
| Ponatinib | Tablet 15 mg (as hydrochloride) | Oral | 60 | 5 | 60 |
| Tablet 45 mg (as hydrochloride) | Oral | 30 | 5 | 30 | |
| Pramipexole | Tablet (extended release) containing pramipexole hydrochloride 1.5 mg | Oral | 30 | 5 | |
| Tablet (extended release) containing pramipexole hydrochloride 2.25 mg | Oral | 30 | 5 | ||
| Tablet (extended release) containing pramipexole hydrochloride 3 mg | Oral | 30 | 5 | ||
| Tablet (extended release) containing pramipexole hydrochloride 3.75 mg | Oral | 30 | 5 | ||
| Tablet (extended release) containing pramipexole hydrochloride 4.5 mg | Oral | 30 | 5 | ||
| Prasugrel | Tablet 5 mg (as hydrochloride) | Oral | 28 | 5 | |
| Tablet 10 mg (as hydrochloride) | Oral | 28 | 5 | ||
| Pravastatin | Tablet containing pravastatin sodium 10 mg | Oral | 30 | 5 | |
| Tablet containing pravastatin sodium 10 mg | Oral | 30 | 11 | ||
| Tablet containing pravastatin sodium 20 mg | Oral | 30 | 5 | ||
| Tablet containing pravastatin sodium 20 mg | Oral | 30 | 11 | ||
| Tablet containing pravastatin sodium 40 mg | Oral | 30 | 5 | ||
| Tablet containing pravastatin sodium 40 mg | Oral | 30 | 11 | ||
| Tablet containing pravastatin sodium 80 mg | Oral | 30 | 5 | ||
| Tablet containing pravastatin sodium 80 mg | Oral | 30 | 11 | ||
| Prazosin | Tablet 1 mg (as hydrochloride) | Oral | 100 | 5 | |
| Tablet 2 mg (as hydrochloride) | Oral | 100 | 5 | ||
| Tablet 5 mg (as hydrochloride) | Oral | 100 | 5 | ||
| Probenecid | Tablet 500 mg | Oral | 100 | 5 | |
| Propranolol | Tablet containing propranolol hydrochloride 10 mg | Oral | 100 | 5 | |
| Tablet containing propranolol hydrochloride 40 mg | Oral | 100 | 5 | ||
| Tablet containing propranolol hydrochloride 160 mg | Oral | 50 | 5 | ||
| Quinapril | Tablet 5 mg (as hydrochloride) | Oral | 30 | 5 | |
| Tablet 10 mg (as hydrochloride) | Oral | 30 | 5 | ||
| Tablet 20 mg (as hydrochloride) | Oral | 30 | 5 | ||
| Quinapril with hydrochlorothiazide | Tablet 10 mg quinapril (as hydrochloride) with 12.5 mg hydrochlorothiazide | Oral | 30 | 5 | |
| Tablet 20 mg quinapril (as hydrochloride) with 12.5 mg hydrochlorothiazide | Oral | 30 | 5 | ||
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | 28 | 5 | |
| Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | 30 | 5 | ||
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral | 28 | 5 | |
| Ramipril | Tablet 1.25 mg | Oral | 30 | 5 | |
| Tablet 2.5 mg | Oral | 30 | 5 | ||
| Tablet 5 mg | Oral | 30 | 5 | ||
| Tablet 10 mg | Oral | 30 | 5 | ||
| Capsule 1.25 mg | Oral | 30 | 5 | ||
| Capsule 2.5 mg | Oral | 30 | 5 | ||
| Capsule 5 mg | Oral | 30 | 5 | ||
| Capsule 10 mg | Oral | 30 | 5 | ||
| Ramipril with felodipine | Tablet 2.5 mg‑2.5 mg (modified release) | Oral | 30 | 5 | |
| Tablet 5 mg‑5 mg (modified release) | Oral | 30 | 5 | ||
| Ranitidine | Tablet 150 mg (as hydrochloride) | Oral | 60 | 5 | |
| Tablet 300 mg (as hydrochloride) | Oral | 30 | 5 | ||
| Tablet, effervescent, 150 mg (as hydrochloride) | Oral | 60 | 5 | ||
| Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL | Oral | 2 | 5 | ||
| Rasagiline | Tablet 1 mg (as mesilate) | Oral | 30 | 5 | |
| Riluzole | Tablet 50 mg | Oral | 56 | 5 | |
| Risedronic acid | Tablet 5 mg | Oral | 28 | 5 | |
| Tablet 35 mg | Oral | 4 | 5 | ||
| Tablet (enteric coated) containing risedronate sodium 35mg | Oral | 4 | 5 | ||
| Tablet containing risedronate sodium 150 mg | Oral | 1 | 5 | ||
| Risedronic acid and calcium | Pack containing 4 enteric coated tablets risedronate sodium 35 mg and 24 tablets calcium 500 mg (as carbonate) | Oral | 1 | 5 | |
| Risedronic acid and calcium with colecalciferol | Pack containing 4 enteric coated tablets risedronate sodium 35 mg and 24 sachets containing granules of calcium carbonate 2.5 g with colecalciferol 22 micrograms | Oral | 1 | 5 | |
| Rivaroxaban | Tablet 15 mg | Oral | 28 | 5 | |
| Tablet 20 mg | Oral | 28 | 5 | ||
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | 30 | 5 | |
| Tablet 5 mg (as calcium) | Oral | 30 | 11 | ||
| Tablet 10 mg (as calcium) | Oral | 30 | 5 | ||
| Tablet 10 mg (as calcium) | Oral | 30 | 11 | ||
| Tablet 20 mg (as calcium) | Oral | 30 | 5 | ||
| Tablet 20 mg (as calcium) | Oral | 30 | 11 | ||
| Tablet 40 mg (as calcium) | Oral | 30 | 5 | ||
| Tablet 40 mg (as calcium) | Oral | 30 | 11 | ||
| Salcatonin | Injection 100 I.U. in 1 mL ampoule | Injection | 15 | 5 | |
| Sapropterin | Tablet (soluble) containing sapropterin hydrochloride 100 mg | Oral | 180 | 5 | |
| Selegiline | Tablet containing selegiline hydrochloride 5 mg | Oral | 100 | 5 | |
| Sevelamer | Tablet containing sevelamer hydrochloride 800 mg | Oral | 180 | 5 | |
| Simvastatin | Tablet 5 mg | Oral | 30 | 5 | |
| Tablet 5 mg | Oral | 30 | 11 | ||
| Tablet 10 mg | Oral | 30 | 5 | ||
| Tablet 10 mg | Oral | 30 | 11 | ||
| Tablet 20 mg | Oral | 30 | 5 | ||
| Tablet 20 mg | Oral | 30 | 11 | ||
| Tablet 40 mg | Oral | 30 | 5 | ||
| Tablet 40 mg | Oral | 30 | 11 | ||
| Tablet 80 mg | Oral | 30 | 5 | ||
| Tablet 80 mg | Oral | 30 | 11 | ||
| Spironolactone | Tablet 25 mg | Oral | 100 | 5 | |
| Tablet 100 mg | Oral | 100 | 5 | ||
| Strontium | Sachet containing granules for oral suspension containing strontium ranelate 2 g | Oral | 28 | 5 | |
| Sulfasalazine | Tablet 500 mg | Oral | 200 | 5 | |
| Tablet 500 mg | Oral | 200 | 11 | ||
| Tablet 500 mg (enteric coated) | Oral | 200 | 5 | ||
| Tablet 500 mg (enteric coated) | Oral | 200 | 11 | ||
| Tamoxifen | Tablet 10 mg (as citrate) | Oral | 60 | 5 | |
| Tablet 20 mg (as citrate) | Oral | 60 | 5 | ||
| Telmisartan | Tablet 40 mg | Oral | 28 | 5 | |
| Tablet 80 mg | Oral | 28 | 5 | ||
| Telmisartan with amlodipine | Tablet 40 mg‑5 mg (as besylate) | Oral | 28 | 5 | |
| Tablet 40 mg‑10 mg (as besylate) | Oral | 28 | 5 | ||
| Tablet 80 mg‑5 mg (as besylate) | Oral | 28 | 5 | ||
| Tablet 80 mg‑10 mg (as besylate) | Oral | 28 | 5 | ||
| Telmisartan with hydrochlorothiazide | Tablet 40 mg‑12.5 mg | Oral | 28 | 5 | |
| Tablet 80 mg‑12.5 mg | Oral | 28 | 5 | ||
| Tablet 80 mg‑25 mg | Oral | 28 | 5 | ||
| Temozolomide | Capsule 5 mg | Oral | 5 | 5 | |
| Capsule 20 mg | Oral | 5 | 5 | ||
| Capsule 100 mg | Oral | 5 | 5 | ||
| Capsule 140 mg | Oral | 5 | 5 | ||
| Capsule 180 mg | Oral | 5 | 5 | ||
| Capsule 250 mg | Oral | 5 | 5 | ||
| Teriparatide | Injection 250 micrograms per mL, 2.4 mL in multi‑dose pre‑filled pen | Injection | 1 | 5 | |
| Testosterone | Capsule containing testosterone undecanoate 40 mg | Oral | 60 | 5 | |
| Transdermal cream 50 mg per mL, 50 mL | Transdermal | 1 | 6 | ||
| Transdermal gel 50 mg in 5 g sachet, 30 | Transdermal | 1 | 5 | ||
| Transdermal patches 12.2 mg, 60 | Transdermal | 1 | 5 | ||
| Transdermal patches 24.3 mg, 30 | Transdermal | 1 | 5 | ||
| Transdermal solution (pump pack) 30 mg per 1.5 mL dose, 60 doses | Transdermal | 1 Pack | 5 | ||
| Theophylline | Tablet 200 mg (sustained release) | Oral | 100 | 5 | |
| Tablet 250 mg (sustained release) | Oral | 100 | 5 | ||
| Tablet 300 mg (sustained release) | Oral | 100 | 5 | ||
| Ticagrelor | Tablet 90 mg | Oral | 56 | 5 | |
| Tiotropium | Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in HandiHaler) | Inhalation by mouth | 30 | 5 | |
| Tiotropium with olodaterol | Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses | Inhalation by mouth | 1 | 5 | 1 |
| Tofacitinib | Tablet 5 mg | Oral | 56 | 5 | |
| Trandolapril | Capsule 500 micrograms | Oral | 28 | 5 | |
| Capsule 1 mg | Oral | 28 | 5 | ||
| Capsule 2 mg | Oral | 28 | 5 | ||
| Capsule 4 mg | Oral | 28 | 5 | ||
| Trandolapril with verapamil | Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release) | Oral | 28 | 5 | |
| Trandolapril with verapamil hydrochloride | Tablet containing trandolapril 2 mg with verapamil hydrochloride 180 mg (sustained release) | Oral | 28 | 5 | |
| Triptorelin | Powder for I.M. injection (prolonged release) 3.75 mg (as embonate) with solvent, syringe and needles | Injection | 1 | 5 | |
| Umeclidinium | Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses | Inhalation by mouth | 1 | 5 | |
| Umeclidinium with vilanterol | Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | 1 | 5 | |
| Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | 30 | 5 | |
| Valsartan | Tablet 80 mg | Oral | 28 | 5 | |
| Tablet 160 mg | Oral | 28 | 5 | ||
| Tablet 320 mg | Oral | 28 | 5 | ||
| Valsartan with hydrochlorothiazide | Tablet 80 mg‑12.5 mg | Oral | 28 | 5 | |
| Tablet 160 mg‑12.5 mg | Oral | 28 | 5 | ||
| Tablet 160 mg‑25 mg | Oral | 28 | 5 | ||
| Tablet 320 mg‑12.5 mg | Oral | 28 | 5 | ||
| Tablet 320 mg‑25 mg | Oral | 28 | 5 | ||
| Verapamil | Tablet containing verapamil hydrochloride 40 mg | Oral | 100 | 5 | |
| Tablet containing verapamil hydrochloride 80 mg | Oral | 100 | 5 | ||
| Tablet containing verapamil hydrochloride 180 mg (sustained release) | Oral | 30 | 5 | ||
| Tablet containing verapamil hydrochloride 240 mg (sustained release) | Oral | 30 | 5 | ||
| Capsule containing verapamil hydrochloride 160 mg (sustained release) | Oral | 30 | 5 | ||
| Capsule containing verapamil hydrochloride 240 mg (sustained release) | Oral | 30 | 5 |
Endnotes
Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Endnotes about misdescribed amendments and other matters are included in a compilation only as necessary.
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.
If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.
Endnote 2—Abbreviation key
| A = Act | o = order(s) |
| ad = added or inserted | Ord = Ordinance |
| am = amended | orig = original |
| amdt = amendment | par = paragraph(s)/subparagraph(s) |
| c = clause(s) | /sub‑subparagraph(s) |
| C[x] = Compilation No. x | pres = present |
| Ch = Chapter(s) | prev = previous |
| def = definition(s) | (prev…) = previously |
| Dict = Dictionary | Pt = Part(s) |
| disallowed = disallowed by Parliament | r = regulation(s)/rule(s) |
| Div = Division(s) | Reg = Regulation/Regulations |
| exp = expires/expired or ceases/ceased to have | reloc = relocated |
| effect | renum = renumbered |
| F = Federal Register of Legislative Instruments | rep = repealed |
| gaz = gazette | rs = repealed and substituted |
| LI = Legislative Instrument | s = section(s)/subsection(s) |
| LIA = Legislative Instruments Act 2003 | Sch = Schedule(s) |
| (md) = misdescribed amendment can be given | Sdiv = Subdivision(s) |
| effect | SLI = Select Legislative Instrument |
| (md not incorp) = misdescribed amendment | SR = Statutory Rules |
| cannot be given effect | Sub‑Ch = Sub‑Chapter(s) |
| mod = modified/modification | SubPt = Subpart(s) |
| No. = Number(s) | underlining = whole or part not |
| commenced or to be commenced |
Endnote 3—Legislation history
| Name | FRLI registration | Commencement | Application, saving and transitional provisions |
| PB 30 of 2009 | 17 Apr 2009 (F2009L01354) | 1 May 2009 (s 2) | |
| PB 45 of 2009 | 28 May 2009 (F2009L02084) | 1 June 2009 (s 2) | — |
| PB 59 of 2009 | 17 June 2009 (F2009L02368) | 1 July 2009 (s 2) | — |
| PB 71 of 2009 | 29 July 2009 (F2009L02982) | 1 Aug 2009 (s 2) | — |
| PB 84 of 2009 | 18 Aug 2009 (F2009L03212) | 1 Sept 2009 (s 2) | — |
| PB 103 of 2009 | 29 Oct 2009 (F2009L04036) | 1 Nov 2009 (s 2) | — |
| PB 115 of 2009 | 30 Nov 2009 (F2009L04346) | 1 Dec 2009 (s 2) | — |
| PB 11 of 2010 | 25 Feb 2010 (F2010L00535) | 1 Mar 2010 (s 2) | — |
| PB 28 of 2010 | 26 Mar 2010 (F2010L00755) | 1 Apr 2010 (s 2) | — |
| PB 42 of 2010 | 28 Apr 2010 (F2010L01035) | 1 May 2010 (s 2) | — |
| PB 53 of 2010 | 26 May 2010 (F2010L01437) | 1 June 2010 (s 2) | — |
| PB 61 of 2010 | 22 June 2010 (F2010L01639) | 1 July 2010 (s 2) | — |
| PB 79 of 2010 | 27 July 2010 (F2010L02194) | 1 Aug 2010 (s 2) | — |
| PB 86 of 2010 | 12 Aug 2010 (F2010L02273) | 1 Sept 2010 (s 2) | — |
| PB 106 of 2010 | 03 Nov 2010 (F2010L02895) | 4 Nov 2010 (s 2(b)) | — |
| PB 119 of 2010 | 30 Nov 2010 (F2010L03116) | 1 Dec 2010 (s 2) | — |
| PB 30 of 2011 | 30 Mar 2011 (F2011L00529) | 1 Apr 2011 (s 2) | — |
| PB 41 of 2011 | 26 May 2011 (F2011L00865) | 1 June 2011 (s 2) | — |
| PB 55 of 2011 | 28 July 2011 (F2011L01548) | 1 Aug 2011 (s 2) | — |
| PB 64 of 2011 | 31 Aug 2011 (F2011L01779) | 1 Sept 2011 (s 2) | — |
| PB 73 of 2011 | 29 Sept 2011 (F2011L01988) | 1 Oct 2011 (s 2) | — |
| PB 92 of 2011 | 30 Nov 2011 (F2011L02502) | 1 Dec 2011 (s 2) | — |
| PB 24 of 2012 | 29 Mar 2012 (F2012L00710) | 1 Apr 2012 (s 2) | — |
| PB 56 of 2012 | 25 July 2012 (F2012L01603) | 1 Aug 2012 (s 2) | — |
| PB 69 of 2012 | 22 Aug 2012 (F2012L01737) | 1 Sept 2012 (s 2) | — |
| PB 86 of 2012 | 26 Sept 2012 (F2012L01931) | 1 Oct 2012 (s 2) | — |
| PB 104 of 2012 | 29 Nov 2012 (F2012L02292) | 1 Dec 2012 (s 2) | — |
| PB 13 of 2013 | 25 Feb 2013 (F2013L00275) | 1 Mar 2013 (s 2) | — |
| PB 28 of 2013 | 30 Apr 2013 (F2013L00705) | 1 May 2013 (s 2) | — |
| PB 50 of 2013 | 29 July 2013 (F2013L01456) | 1 Aug 2013 (s 2) | — |
| PB 60 of 2013 | 16 Aug 2013 (F2013L01581) | 1 Sept 2013 (s 2) | — |
| PB 83 of 2013 | 29 Nov 2013 (F2013L02014) | 1 Dec 2013 (s 2) | — |
| PB 25 of 2014 | 26 Mar 2014 (F2014L00355) | 1 Apr 2014 (s 2) | — |
| PB 34 of 2014 | 11 Apr 2014 (F2014L00402) | 1 May 2014 (s 2) | — |
| PB 39 of 2014 | 21 May 2014 (F2014L00591) | 1 June 2014 (s 2) | — |
| PB 60 of 2014 | 31 July 2014 (F2014L01062) | 1 Aug 2014 (s 2) | — |
| PB 69 of 2014 | 25 Aug 2014 (F2014L01123) | 1 Sept 2014 (s 2) | — |
| PB 75 of 2014 | 26 Sept 2014 (F2014L01293) | 1 Oct 2014 (s 2) | — |
| PB 84 of 2014 | 23 Oct 2014 (F2014L01392) | 1 Nov 2014 (s 2) | — |
| PB 92 of 2014 | 28 Nov 2014 (F2014L01608) | 1 Dec 2014 (s 2) | |
| PB 106 of 2014 | 23 Dec 2014 (F2014L01799) | 1 Jan 2015 (s 2) | — |
| PB 8 of 2015 | 15 Jan 2015 (F2015L00043) | 1 Feb 2015 (s 2) | — |
| PB 17 of 2015 | 25 Feb 2015 (F2015L00206) | 1 Mar 2015 (s 2) | — |
| PB 36 of 2015 | 25 Mar 2015 (F2015L00334) | 1 Apr 2015 (s 2) | — |
| PB 46 of 2015 | 24 Apr 2015 (F2015L00593) | 1 May 2015 (s 2) | — |
| PB 57 of 2015 | 30 June 2015 (F2015L01062) | 1 July 2015 (s 2) | — |
| PB 71 of 2015 | 31 July 2015 (F2015L01206) | 1 Aug 2015 (s 2) | — |
| PB 81 of 2015 | 28 Aug 2015 (F2015L01349) | 1 Sept 2015 (s 2) | — |
| PB 93 of 2015 | 30 Sept 2015 (F2015L01540) | 1 Oct 2015 (s 2) | — |
| PB 103 of 2015 | 28 Oct 2015 (F2015L01704) | 1 Nov 2015 (s 2) | — |
| PB 110 of 2015 | 1 Dec 2015 (F2015L01899) | 1 Dec 2015 (s 2) | — |
Endnote 4—Amendment history
| Provision affected | How affected |
| Schedule 1 | |
| Schedule 1........................ | am. PB 45, 59, 71, 84, 103 and 115 of 2009; PB 11, 28, 42, 53, 61, 79, 86, 106 and 119 of 2010; PB 30, 41, 55, 64, 73 and 92 of 2011; PB 24, 56, 69, 86 and 104 of 2012; PB 13, 28, 50, 60 and 83 of 2013; PB 25, 34, 39, 60, 69, 75, 84, 92 and 106 of 2014; PB 8, 17, 36, 46, 57, 71, 81, 93, 103 and 110 of 2015 |
Actions
Download as PDF
Download as Word Document
Cases Citing This Decision
0
Cases Cited
0
Statutory Material Cited
0